Xbrane Biopharma releases Annual report for 2020

Annual

English

IR

News

Regulatory

Report

VPML

Xbrane Biopharma AB’s annual report for 2020 is now available at the company’s website, www.xbrane.com. The annual report includes the corporate governance report and the sustainability report for 2020.

In regard to ESMA’s recommendations the annual report also includes the operational and financial impact the company sees due to COVID-19 pandemic (CEO Comments and Administration Report). Xbrane will continue to assess the situation and will be providing a further update in the interim report for January-March scheduled on May 6, 2021.

The annual report is distributed to the shareholders and others that made such request. The annual report can also be ordered from Xbrane Biopharma on the following address:

Xbrane Biopharma AB
Retzius väg 8 22
171 65 Solna
Sweden

Or via e-mail: ir@xbrane.com

Contacts

Martin Åmark, CEO
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Anette Lindqvist, CFO / IR
M: +46 (0) 763 256 090
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the SEK 106 billions ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally three biosimilars in its pipeline targeting SEK 100 billions in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-03-31 08:00 CEST.

Attachments

Xbrane Biopharma AB Annual report 2020